Plain-English translation of NCT06035016 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is testing a new targeted medication called pyrotinib combined with a chemotherapy drug (capecitabine) as a follow-up treatment after breast cancer surgery. The study wants to see if this combination is effective and safe for women whose breast cancer has a specific marker called HER2-positive. The researchers will compare how well this new combination works compared to other treatment options that doctors might choose.
HER2-positive breast cancer can be aggressive, and even after surgery, there is a risk it could come back. Researchers want to find better ways to reduce that risk and improve long-term outcomes for patients with this type of cancer.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would be assigned to either receive the new medication combination or your doctor's choice of other treatment. If you receive the new combination, you would take pyrotinib as a daily pill for 3 weeks, followed by a 1-week break (repeating this cycle), along with capecitabine taken twice daily for 2 weeks of each cycle. You would have regular clinic visits and blood tests to monitor how well the treatment is working and check for any side effects.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China
Sponsor
Peking Union Medical College Hospital
Enrollment target
~300 participants
Started
June 2023
Primary completion
June 2027
Age range
18 Years – 75 Years
Sex
Female only
Last updated on clinicaltrials.gov in September 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xuefei Wang
Peking Union Medical College Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.